RB
MCID: RTN024
MIFTS: 74

Retinoblastoma (RB) malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Retinoblastoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Retinoblastoma:

Name: Retinoblastoma 52 11 71 23 48 24 25 54 27 12 50 13 68
Trilateral Retinoblastoma 11 27 13 68
Rb 11 48 25 70
Glioma, Retinal 71 25
Childhood Cancer Retinoblastoma 70
Malignant Neoplasm of Retina 68
Eye Cancer, Retinoblastoma 48
 
Retinoblastoma, Trilateral 52
Neuroblastoma of Retina 11
Rb - Retinoblastoma 11
Retinal Neoplasms 68
Retinal Cancer 48
Retinal Tumor 48

Characteristics:

Orphanet epidemiological data:

54
retinoblastoma:
Inheritance: Autosomal dominant,Not applicable; Prevalence: <1/1000000 (Europe),1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Antenatal,Childhood,Infancy; Age of death: any age

HPO:

64

GeneReviews:

23
Penetrance: see genotype-phenotype correlations...


Classifications:

Orphanet: 54 
Rare eye diseases


External Ids:

OMIM52 180200
Disease Ontology11 DOID:4647, DOID:768
MeSH39 D012175
NCIt45 C6956, C7541
Orphanet54 ORPHA790
MESH via Orphanet40 D012175
UMLS via Orphanet69 C0035335
ICD10 via Orphanet31 C69.2
MedGen37 C1867262

Summaries for Retinoblastoma

About this section
NIH Rare Diseases:48 Retinoblastoma (rb) is a rare type of eye cancer in the retina that typically develops before the age of 5. it usually affects only one eye, but 1/3 of children with rb develop cancer in both eyes. the first sign is typically a visible whiteness in the pupil called "cat's eye reflex" or leukocoria, which is particularly noticeable in photographs taken with a flash. other signs and symptoms include strabismus; persistent eye pain, redness or irritation; and blindness or poor vision in the affected eye(s). retinoblastoma is caused by mutations in the rb1 gene. in about 60% of people with retinoblastoma, mutations are not inherited and occur only in retinal cells. in the other 40% of individuals, mutations are inherited from a parent in an autosomal dominant pattern and can be found in all body cells. retinoblastoma that is caused by an inherited mutation is called hereditary retinoblastoma. hereditary retinoblastoma usually occurs at a younger age than retinoblastoma that is not inherited (15 months vs. 24 months). retinoblastoma that occurs in only one eye is usually not inherited. retinoblastoma that occurs in both eyes is thought to be inherited. last updated: 4/4/2012

MalaCards based summary: Retinoblastoma, also known as trilateral retinoblastoma, is related to extraocular retinoblastoma and intraocular retinoblastoma, and has symptoms including Array, cleft palate and leukocoria. An important gene associated with Retinoblastoma is RB1 (RB Transcriptional Corepressor 1), and among its related pathways are Interactome of polycomb repressive complex 2 (PRC2) and ID signaling pathway. The drug cyclophosphamide has been mentioned in the context of this disorder. Affiliated tissues include eye, retina and breast, and related mouse phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and craniofacial.

Disease Ontology:11 A retinal cell cancer and malignant neoplasm of retina and neuroblastoma and neuroendocrine tumors that derives from the tissues of the retina.

Genetics Home Reference:25 Retinoblastoma is a rare type of eye cancer that usually develops in early childhood, typically before the age of 5. This form of cancer develops in the retina, which is the specialized light-sensitive tissue at the back of the eye that detects light and color.

OMIM:52 Retinoblastoma (RB) is an embryonic malignant neoplasm of retinal origin. It almost always presents in early childhood... (180200) more...

UniProtKB/Swiss-Prot:70 Childhood cancer retinoblastoma: Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.

Wikipedia:71 Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina,... more...

GeneReviews for NBK1452

Related Diseases for Retinoblastoma

About this section

Diseases in the Retinoblastoma family:

Familial Retinoblastoma

Diseases related to Retinoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 231)
idRelated DiseaseScoreTop Affiliating Genes
1extraocular retinoblastoma32.5CCND1, CCND3, CDK4, E2F1, E2F2, E2F3
2intraocular retinoblastoma12.2
3bilateral retinoblastoma12.2
4unilateral retinoblastoma12.2
5familial retinoblastoma12.1
6pediatric intraocular retinoblastoma12.0
7pediatric extraocular retinoblastoma12.0
8non-hereditary retinoblastoma11.8
9roberts syndrome11.5
10ocular cancer11.1
11blastoma11.0
12retinal cancer11.0
13respiratory bronchiolitis-interstitial lung disease syndrome10.8
14sc phocomelia syndrome10.8
15chromosome 13q14 deletion syndrome10.7
16norrie disease10.7
17retinal disease10.7
18hiv-110.3
19osteomyelitis10.3CDK4, MDM2, RB1
20apocrine sweat gland neoplasm10.3CDK4, MDM2, RB1
21rommen mueller sybert syndrome10.3CDK4, MDM2
22cervical verrucous carcinoma10.3CCND1, MDM2, RB1
23episodic ataxia10.2CCND1, CDK4, MDM2
24primary eye hypotony10.2CDK4, MDM2
25amelogenesis imperfecta-gingival hyperplasia syndrome10.2CDK4, MDM2
26indolent systemic mastocytosis10.2RB1, RBL1
27adult astrocytic tumour10.2CDK4, E2F1, MDM2, RB1
28breast cancer10.2
29placenta praevia10.2CCND1, CDK4, E2F3, MDM2, RB1
30retinitis10.1
31neuronitis10.1
32prostatitis10.1
33lung cancer10.1
34squamous cell carcinoma10.1
35melanoma10.1
36leukemia10.1
37ectodermal dysplasia10.1CCND1, CDK4, MDM2
38melanoma metastasis10.0CCND1, CCND3, CDK4, MDM2
39sarcoma10.0
40lymphoma10.0
41cervicitis10.0
42adenocarcinoma10.0
43prostate cancer9.9
44leiomyosarcoma9.9
45cellulitis9.9
46thyroiditis9.9
47endotheliitis9.9
48hepatocellular carcinoma9.9
49orbital cellulitis9.9
50esophagitis9.9

Graphical network of the top 20 diseases related to Retinoblastoma:



Diseases related to retinoblastoma

Symptoms & Phenotypes for Retinoblastoma

About this section

Symptoms by clinical synopsis from OMIM:

180200

Clinical features from OMIM:

180200

Human phenotypes related to Retinoblastoma:

 54 64 (show all 11)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 retinoblastoma64 54 Very frequent (99-80%) HP:0009919
2 cleft palate64 HP:0000175
3 leukocoria64 HP:0000555
4 leukemia64 HP:0001909
5 lymphoma64 HP:0002665
6 osteosarcoma64 HP:0002669
7 retinal calcification64 HP:0007862
8 vitreous hemorrhage64 HP:0007902
9 pinealoma64 HP:0010799
10 vitritis64 HP:0011531
11 ewing's sarcoma64 HP:0012254

GenomeRNAi Phenotypes related to Retinoblastoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00104-A-010.3CCND1, E2F3, RBBP4, RBL1

MGI Mouse Phenotypes related to Retinoblastoma according to GeneCards Suite gene sharing:

41 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538210.0CCND1, E2F4, MDM2, RB1, RBBP7, RBL1
2MP:00053679.6ARID4A, CDK4, E2F2, MDM2, RB1, RBL1
3MP:00053919.4CCND1, CCND3, CDK4, E2F1, E2F2, E2F3
4MP:00053819.3CCND1, CDK4, E2F1, E2F3, E2F4, MDM2
5MP:00053899.3ARID4A, CCND1, CDK4, E2F1, E2F3, E2F4
6MP:00053709.3ARID4A, CCND3, CDK4, E2F2, MDM2, RB1
7MP:00053909.2ARID4A, CCND1, E2F1, E2F3, E2F4, MDM2
8MP:00053809.2CDK4, E2F1, E2F3, E2F4, MDM2, RB1
9MP:00028739.0CCND1, CCND3, CDK4, E2F1, E2F2, E2F3
10MP:00053889.0ARID4A, CCND1, CCND3, E2F1, E2F2, E2F3
11MP:00053858.9ARID4A, CCND1, CCND3, CDK4, E2F1, E2F3
12MP:00020068.8ARID4A, CCND1, CCND3, CDK4, E2F1, E2F4
13MP:00053848.8ARID4A, CCND1, CDK4, E2F1, E2F2, E2F3
14MP:00053878.7ARID4A, CCND1, CCND3, CDK4, E2F1, E2F2
15MP:00107718.6ARID4A, CCND1, CDK4, E2F1, E2F2, E2F3
16MP:00053798.5ARID4A, CCND1, CCND3, CDK4, E2F1, E2F2
17MP:00053978.5ARID4A, CCND1, CCND3, CDK4, E2F1, E2F2
18MP:00053788.4ARID4A, CCND1, CCND3, CDK4, E2F1, E2F2
19MP:00107688.1ARID4A, CCND1, CCND3, CDK4, DDX1, E2F1

Drugs & Therapeutics for Retinoblastoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Ibrance16 44 PALBOCICLIB Pfizer February 2015
FDA Label: Ibrance
Disease/s that Drug Treats:ER-positive, HER2-negative breast cancer
Indications and Usage:16 IBRANCE is a kinase inhibitor indicated in combination with letrozole for thetreatment of postmenopausal women with estrogen receptor (ER)-positive,human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer as initial endocrine-based therapy for their metastatic disease. Thisindication is approved under accelerated approval based on progression-freesurvival (PFS). Continued approval for this indication may be contingentupon verification and description of clinical benefit in a confirmatory trial. (1)
DrugBank Targets:14 1. Cyclin-dependent kinase 4;2. Cyclin-dependent kinase 6
Mechanism of Action:16 
Target: cyclin-dependent kinase (CDK) 4 and 6
Action: inhibitor
FDA: Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4/6 aredownstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reducedcellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progressionof the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with thecombination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)phosphorylation resulting in reduced E2F expression and signaling and increased growth arrestcompared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lineswith the combination of palbociclib and antiestrogens leads to increased cell senescence, which wassustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positivebreast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increasedthe inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drugalone.
2
Tasigna16 44 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
FDA Label: Tasigna
Disease/s that Drug Treats:chronic myelogenous leukemia
Indications and Usage:16 Tasigna is a kinase inhibitor indicated for:The treatment of newly diagnosed adult patients with Philadelphiachromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML inadult patients resistant to or intolerant to prior therapy that included imatinib.(1.2)--------------
DrugBank Targets:14 1. Tyrosine-protein kinase ABL1;2. Mast/stem cell growth factor receptor Kit
Mechanism of Action:16 
Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF)
Action: inhibitor of signal transduction
FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation ofthe kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murineleukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of theassays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 outof 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).
3
Kalydeco16 IVACAFTOR Vertex Pharmaceuticals January of 2012
FDA Label: Kalydeco
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:16 KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:14 Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:16 
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.

Drugs for Retinoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 149)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1126933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
2
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 29222068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
3
CarboplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
4
Itraconazoleapproved, investigationalPhase 415884625-61-655283
Synonyms:
(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one
(+/-)-1-[( R *)- sec -butyl]-4-[ p -[4-[ p -[[(2 R *,4 S *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-(DELTA) 2 1,2,4-triazolin-5-one mixture with (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4- [ p -[[(2 S *,4 R *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl] phenyl]-(DELTA) 2 -1,2,4-triazolin-5-one
(1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one
2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)
4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
84604-65-9
84625-61-6
AC-542
AC1L1GQ5
AC1L1IRU
AC1OCEL7
AC1Q6EZ3
AKOS000280875
Ambap84625-61-6
BIDD:GT0796
BRN 6042047
C35H38Cl2N8O4
CHEBI:6076
CHEMBL22587
CHEMBL882
CID3793
CID55283
CID6917738
CID9961741
CPD000058959
Canadiol
D00350
DB01167
EINECS 283-347-2
FT-0082511
HMS2051K14
HMS2090M20
Hyphanox
I01-1043
I0732
ITC
ITCZ
ITZ
Intraconazole
 
Itraconazol
Itraconazol [Spanish]
Itraconazole
Itraconazole & Bovine Lactoferrin
Itraconazole & Nyotran
Itraconazole & Nyotran(Liposomal Nystatin)
Itraconazole (JAN/USAN)
Itraconazole [USAN:BAN:INN:JAN]
Itraconazole oral solution
Itraconazolum
Itraconazolum [Latin]
Itrizole
Itrizole (TN)
Itrizole (tn)
LS-1843
MLS000028582
MLS000759472
MLS000863291
MLS001148245
MolPort-000-883-864
MolPort-003-848-295
NCGC00089812-03
Oriconazole
Oriconazole, R51211, Sporanox
Orungal
Prokanazol
R 51211
R-51211
S2476_Selleck
SAM001246679
SMR000058959
Sempera
Spherazole
Sporal
Sporanos
Sporanox
Sporanox (TN)
Sporanox (tn)
Sporonox
TL8005525
Triasporn
UNII-304NUG5GF4
cis-Itraconazole
itraconazole
5
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
6
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
8
Ginsengapproved, nutraceuticalPhase 4, Phase 29650647-08-0
Synonyms:
Aralia ginseng root
Asian ginseng
Asian ginseng root
Chinese ginseng root
Ginseng (panax ginseng)
Ginseng extract
Ginseng, asian
Hong shen root
Insam root
Korean ginseng
 
Korean ginseng root
Ninjin root
Panax ginseng
Panax ginseng root
Panax ginseng root extract
Panax schinseng root
Panax verus root
Red ginseng
Ren seng root
Ren shen
Ren shen root
True ginseng root
9Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 15069
10Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 15657
11Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 15602
12Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 11269
13Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
14Ibandronic acidPhase 480
15Adjuvants, ImmunologicPhase 4, Phase 3, Phase 2, Phase 12554
16Bone Density Conservation AgentsPhase 4, Phase 23376
17
CurcuminPhase 4146458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
18Liver ExtractsPhase 4, Phase 2, Phase 14067
19DiphosphonatesPhase 4450
20Steroid Synthesis InhibitorsPhase 4, Phase 2, Phase 11763
21Cytochrome P-450 Enzyme InhibitorsPhase 43917
22Cytochrome P-450 CYP3A InhibitorsPhase 41715
23Antifungal AgentsPhase 4, Phase 2, Phase 13696
24HormonesPhase 4, Phase 2, Phase 114415
25Hormone AntagonistsPhase 4, Phase 2, Phase 113180
26Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 113168
27HydroxyitraconazolePhase 4158
28
AllantoinNutraceuticalPhase 41097-59-6204
Synonyms:
(S)-allantoin
2,5-Dioxo-4-imidazolidinyl-urea
4-Ureido-2,5-Imidazolidinedione
5-Ureido-Hydantoin
5-Ureidohydantoin
5-Ureidohydrantoin
AVC/Dienestrolcream
Alantan
Allantoin
Allantol
 
Alloxantin
Cordianine
D00121
Fancol TOIN
Glyoxyldiureid
Glyoxyldiureide
Glyoxylic diureide
N-(2,5-Dioxo-4-imidazolidinyl)urea
Psoralon
Sebical
Septalan
29
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
30
ThiotepaapprovedPhase 3, Phase 2, Phase 122652-24-45453
Synonyms:
 
Thioplex
31
CisplatinapprovedPhase 3, Phase 2277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
32
MesnaapprovedPhase 3, Phase 2, Phase 12633375-50-6598
Synonyms:
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-mercaptoethanesulfonic acid
2-mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-sulfanylethylsulfonate
 
CoM
Coenzima M
Coenzym M
Coenzyme M
HS-CoM
reduced CoM
reduced coenzyme M
β-mercaptoethanesulfonic acid
33
Doxorubicinapproved, investigationalPhase 3, Phase 2175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
34
Topotecanapproved, investigationalPhase 3, Phase 2, Phase 1349119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
35
DoxilApproved June 1999Phase 3, Phase 2175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
36Immunosuppressive AgentsPhase 3, Phase 2, Phase 1, Early Phase 113086
37
IodinePhase 3, Phase 2, Phase 15707553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
38cadexomer iodinePhase 3, Phase 2, Phase 1537
39topoisomerase I inhibitorsPhase 3, Phase 2, Phase 11370
40Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 1, Early Phase 14603
41Anti-Infective Agents, LocalPhase 3, Phase 21880
42Antibiotics, AntitubercularPhase 3, Phase 2, Phase 17180
43Alkylating AgentsPhase 3, Phase 2, Phase 1, Early Phase 14827
44Antirheumatic AgentsPhase 3, Phase 2, Phase 1, Early Phase 110956
45MicronutrientsPhase 3, Phase 26001
46Trace ElementsPhase 3, Phase 26001
47Anti-Bacterial AgentsPhase 3, Phase 2, Phase 1, Early Phase 111226
48AnestheticsPhase 3, Phase 29596
49
RanibizumabapprovedPhase 2, Phase 1486347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
50
Arsenic trioxideapproved, investigationalPhase 21221327-53-3518740
Synonyms:
28380-38-3
AC1L24QX
AI3-01163
Acide Arsenieux
Acide Arsenieux [French]
Acide arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Anhydride arsenieux [French]
Arseneous anhydride
Arseneous oxide
Arseni Trioxydum
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic Oxidearsenous Trioxide
Arsenic Sesquioxide
Arsenic Trioxide [UN1561] [Poison]
Arsenic blanc [French]
Arsenic oxide
Arsenic oxide (As2O3)
Arsenic sesquioxide
Arsenic trioxide (JP15/USAN)
Arsenic trioxide [JAN]
Arsenic trioxide [UN1561] [Poison]
Arsenic(III) oxide
Arsenic(III) trioxide
Arsenic, White
Arsenicum Album
Arsenicum album
Arsenigen Saure
Arsenigen Saure [German]
Arsenigen saure [German]
Arsenious Acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious Trioxide
Arsenious trioxide
Arsenite
Arsenolite
Arsenous Acid
 
Arsenous Acid Anhydride
Arsenous Anhydride
Arsenous Oxide
Arsenous Oxide Anhydride
Arsenous oxide [ISO]
Arsenox
Arsentrioxide
Arsodent
C006632
CCRIS 5455
CHEMBL405991
CID14888
Caswell No. 059
Claudelite
Claudetite
Crude Arsenic
D02106
Di-Arsenic Trioxide
Diarsenic Trioxide
Diarsenic trioxide
Diarsonic Trioxide
EINECS 215-481-4
EPA Pesticide Chemical Code 007001
HSDB 419
LS-761
MolPort-006-823-587
Oxyde Arsenieux
Oxyde Arsenieux [ISO-French]
Poison Flour
RCRA waste no. P012
Rcra waste number P012
Tetraarsenic hexaoxide
Trisenox
Trisenox (TN)
Trixenox
UN 1561
UN1561
UNII-S7V92P67HO
White Arsenic
White arsenic
arsenic trioxide
arsenic(3+)
naonobin
oxygen(2-)

Interventional clinical trials:

(show top 50)    (show all 114)
idNameStatusNCT IDPhase
1CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular RetinoblastomaCompletedNCT02319486Phase 4
2Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationCompletedNCT00336531Phase 4
3Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate SupplementationCompletedNCT02249741Phase 4
4The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile DysfunctionCompletedNCT02413099Phase 4
5Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical StudyCompletedNCT02204826Phase 4
6G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorNot yet recruitingNCT02933333Phase 4
7Carboplatin Periocular Injection for RetinoblastomaUnknown statusNCT02137928Phase 3
8Does Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy?Unknown statusNCT01809522Phase 3
9Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular RetinoblastomaCompletedNCT00072384Phase 3
10Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular RetinoblastomaCompletedNCT00079417Phase 3
11Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed RetinoblastomaCompletedNCT00335738Phase 3
12Adjuvant Chemotherapy for High-risk Retinoblastoma After EnucleationRecruitingNCT01906814Phase 3
13Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular RetinoblastomaActive, not recruitingNCT00554788Phase 3
14Study of Treatment for Patients With Cancer of the Eye -RetinoblastomaActive, not recruitingNCT00186888Phase 3
15Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With CancerActive, not recruitingNCT01987596Phase 3
16Efficacy Study of Lucentis in the Treatment of RetinoblastomaUnknown statusNCT01899066Phase 2
17Chemotherapy Treatment for Children With Intraocular Germ-Line RetinoblastomaUnknown statusNCT00179920Phase 2
18Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular DementiaUnknown statusNCT01761227Phase 2
19Chemotherapy in Treating Patients With RetinoblastomaCompletedNCT00002675Phase 2
20Carboplatin Plus Vincristine in Treating Children With RetinoblastomaCompletedNCT00002794Phase 2
21Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With RetinoblastomaCompletedNCT00004006Phase 2
22Intra-arterial Chemotherapy(Chemosurgery) for RetinoblastomaCompletedNCT00901238Phase 1, Phase 2
23Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.CompletedNCT01291017Phase 2
24Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00006102Phase 2
25High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid TumorsCompletedNCT00003173Phase 2
26Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid TumorsCompletedNCT00024258Phase 2
27Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2
28Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare CancerCompletedNCT00002515Phase 2
29An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2
30Intra-arterial Chemotherapy for Children With RetinoblastomaRecruitingNCT00906113Phase 1, Phase 2
31Protocol for the Study and Treatment of Participants With Intraocular RetinoblastomaRecruitingNCT01783535Phase 2
32Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)RecruitingNCT02870907Phase 2
33Conservative Treatments of RetinoblastomaRecruitingNCT02866136Phase 2
34Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerRecruitingNCT03130439Phase 2
35Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyRecruitingNCT02334527Phase 2
36Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB ExpressionRecruitingNCT02555189Phase 1, Phase 2
37A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation TherapyRecruitingNCT02607124Phase 1, Phase 2
38Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibRecruitingNCT01907607Phase 2
39PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialRecruitingNCT02624973Phase 2
40Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell CancersRecruitingNCT02487095Phase 1, Phase 2
41Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral RetinoblastomaActive, not recruitingNCT00110110Phase 2
42A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerActive, not recruitingNCT02059213Phase 2
43A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)Active, not recruitingNCT02806648Phase 2
44Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerActive, not recruitingNCT00445965Phase 2
45Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerActive, not recruitingNCT00721409Phase 2
46A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced BActive, not recruitingNCT01684215Phase 2
47Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell CarcinomaNot yet recruitingNCT03024489Phase 1, Phase 2
48Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From GuatemalaTerminatedNCT01857752Phase 2
49Intra-arterial Chemotherapy for the Treatment of Intraocular RetinoblastomaTerminatedNCT01293539Phase 2
50Proton Beam Radiation Therapy for Intraocular and Periocular RetinoblastomaTerminatedNCT00432445Phase 2

Search NIH Clinical Center for Retinoblastoma

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Retinoblastoma

About this section

Genetic tests related to Retinoblastoma:

id Genetic test Affiliating Genes
1 Retinoblastoma, Trilateral27
2 Retinoblastoma27 24 RB1

Anatomical Context for Retinoblastoma

About this section

MalaCards organs/tissues related to Retinoblastoma:

36
Eye, Retina, Breast, Lung, Prostate, Testes, Pineal

Publications for Retinoblastoma

About this section

Articles related to Retinoblastoma:

(show top 50)    (show all 2483)
idTitleAuthorsYear
1
Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235. (28445155)
2017
2
Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma. (28420213)
2017
3
Treatments for Retinoblastoma Then and Now. (28030718)
2017
4
EpCAM antibody-conjugated mesoporous silica nanoparticles to enhance the anticancer efficacy of carboplatin in retinoblastoma. (28482574)
2017
5
MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma. (27837373)
2017
6
Long non-coding RNA CCAT1 promotes human retinoblastoma SO-RB50 and Y79 cells through negative regulation of miR-218-5p. (28088735)
2017
7
RETINOBLASTOMA RELATED1 mediates germline entry in Arabidopsis. (28450583)
2017
8
Related visual impairment to mother-infant interaction and development in infants with bilateral retinoblastoma. (28478852)
2017
9
A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma. (28106538)
2017
10
Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding. (28092395)
2017
11
A multidisciplinary approach to improving the care and outcomes of patients with retinoblastoma at a pediatric cancer hospital in Egypt. (28085527)
2017
12
Proliferative Vitreoretinopathy in Treated Retinoblastoma. (28435935)
2017
13
Tetramethylpyrazine-mediated regulation of CXCR4 in retinoblastoma is sensitive to cell density. (28447713)
2017
14
MiR-26a downregulates retinoblastoma in colorectal cancer. (28443472)
2017
15
Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation. (28481041)
2017
16
L1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma. (28061460)
2017
17
Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. (28432112)
2017
18
Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience. (28089679)
2017
19
Enhanced cytotoxic activity of AgNPs on retinoblastoma Y79 cell lines synthesised using marine seaweed Turbinaria ornata. (28476956)
2017
20
SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/I^-catenin signaling pathway. (28485721)
2017
21
Intra-arterial chemotherapy for retinoblastoma: Two-year results from tertiary eye-care center in India. (28513496)
2017
22
Functional dissection of the role of UHRF1 in the regulation of retinoblastoma methylome. (28467809)
2017
23
Analysis of aqueous humor concentrations of cytokines in retinoblastoma. (28486560)
2017
24
Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22. (28476787)
2017
25
Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. (28069617)
2017
26
Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation. (28528011)
2017
27
MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5. (28351331)
2017
28
Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions. (28505181)
2017
29
Psychosocial determinants for treatment decisions in familial retinoblastoma. (28085520)
2017
30
Conservation and divergence of C-terminal domain structure in the retinoblastoma protein family. (28439018)
2017
31
Evaluation of high-risk features of primary enucleation of patients with retinoblastoma in a tertiary center of a developing country in the era of intra-arterial chemotherapy. (28058667)
2017
32
Evolution of Chemotherapy Approaches for the Treatment of Intraocular Retinoblastoma: A Comprehensive Review. (27898618)
2017
33
Long-term Visual Acuity, Strabismus and Nystagmus Outcomes Following Multimodality Treatment in Group D Retinoblastoma Eyes. (28501391)
2017
34
Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. (28034080)
2017
35
Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-I_B inflammation signals. (27133446)
2016
36
Proteomic analysis of differentially expressed proteins in vitreous humor of patients with retinoblastoma using iTRAQ-coupled ESI-MS/MS approach. (27488116)
2016
37
Alteration in Methylation Pattern of Retinoblastoma 1 Gene Promotor Region in Intestinal Metaplasia with or without Helicobacter pylori and Gastric Cancer Patients. (27629734)
2016
38
Hereditary Diffuse Infiltrating Retinoblastoma. (24892564)
2016
39
Next-generation sequencing-based method shows increased mutation detection sensitivity in an Indian retinoblastoma cohort. (27582626)
2016
40
Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma. (27033599)
2016
41
d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway. (27600289)
2016
42
Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. (27966456)
2016
43
Immunohistochemical analysis of retinoblastoma cell phenotype using neuronal and glial cell markers. (28076568)
2016
44
Combination of genetic variants in cyclin D1 and retinoblastoma genes predict clinical outcome in oral cancer patients. (26459309)
2016
45
Therapeutic Options for Retinoblastoma. (27218786)
2016
46
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. (27634906)
2016
47
Forced Trefoil Factor Family Peptide 3 (TFF3) Expression Reduces Growth, Viability, and Tumorigenicity of Human Retinoblastoma Cell Lines. (27626280)
2016
48
Long non-coding RNA HOTAIR regulates proliferation and invasion via activating Notch signalling pathway in retinoblastoma. (27966488)
2016
49
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. (27647547)
2016
50
Curcumin exerts antitumor effects in retinoblastoma cells by regulating the JNK and p38 MAPK pathways. (27432244)
2016

Variations for Retinoblastoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Retinoblastoma:

70 (show all 22)
id Symbol AA change Variation ID SNP ID
1RB1p.Glu72GlnVAR_005572
2RB1p.Glu137AspVAR_005573rs3092902
3RB1p.Ile185ThrVAR_005574
4RB1p.Arg358GlnVAR_005575rs767011440
5RB1p.Met457ArgVAR_005576
6RB1p.His549TyrVAR_005578
7RB1p.Ser567LeuVAR_005579rs137853292
8RB1p.Ala635ProVAR_005580
9RB1p.Val654GluVAR_005581
10RB1p.Arg661TrpVAR_005582rs137853294
11RB1p.Leu662ProVAR_005583
12RB1p.His673ProVAR_005584
13RB1p.Gln685ProVAR_005585
14RB1p.Cys706TyrVAR_005586
15RB1p.Cys712ArgVAR_005587rs137853296
16RB1p.Asn803LysVAR_005588
17RB1p.Arg358GlyVAR_010046
18RB1p.Lys447GlnVAR_010048
19RB1p.Lys530ArgVAR_010049
20RB1p.Leu657ProVAR_010050
21RB1p.Arg500GlyVAR_011580
22RB1p.Lys616GluVAR_011581

Clinvar genetic disease variations for Retinoblastoma:

5 (show all 116)
id Gene Variation Type Significance SNP ID Assembly Location
1RB1NM_ 000321.2(RB1): c.1723C> T (p.Gln575Ter)SNVPathogenicrs587778864GRCh37Chr 13, 49027156: 49027156
2RB1NM_ 000321.2(RB1): c.1735C> T (p.Arg579Ter)SNVPathogenic/ Likely pathogenicrs121913305GRCh37Chr 13, 49027168: 49027168
3RB1NM_ 000321.2(RB1): c.1738G> T (p.Glu580Ter)SNVPathogenicrs587778858GRCh37Chr 13, 49027171: 49027171
4RB1NG_ 009009.1: g.154289dupAduplicationPathogenic
5RB1NM_ 000321.2(RB1): c.1909C> T (p.Gln637Ter)SNVPathogenicrs587778833GRCh37Chr 13, 49030434: 49030434
6RB1NM_ 000321.2(RB1): c.1925T> A (p.Leu642Ter)SNVPathogenicrs587778865GRCh37Chr 13, 49030450: 49030450
7RB1NM_ 000321.2(RB1): c.1927A> G (p.Lys643Glu)SNVPathogenicrs587778866GRCh37Chr 13, 49030452: 49030452
8RB1NM_ 000321.2(RB1): c.1960+5G> ASNVPathogenicrs587778871GRCh37Chr 13, 49030490: 49030490
9RB1NM_ 000321.2(RB1): c.1961-2A> TSNVPathogenicrs587778867GRCh37Chr 13, 49033822: 49033822
10RB1NM_ 000321.2(RB1): c.1973C> A (p.Ala658Asp)SNVPathogenicrs587778834GRCh37Chr 13, 49033836: 49033836
11RB1NM_ 000321.2(RB1): c.2101G> A (p.Asp701Asn)SNVPathogenicrs587778859GRCh37Chr 13, 49033964: 49033964
12RB1NM_ 000321.2(RB1): c.2107-1G> CSNVPathogenicrs587778860GRCh37Chr 13, 49037866: 49037866
13RB1NM_ 000321.2(RB1): c.2164A> T (p.Lys722Ter)SNVPathogenicrs587778849GRCh37Chr 13, 49037924: 49037924
14RB1NM_ 000321.2(RB1): c.2197C> T (p.His733Tyr)SNVPathogenicrs587778835GRCh37Chr 13, 49037957: 49037957
15RB1NM_ 000321.2(RB1): c.2209G> T (p.Glu737Ter)SNVPathogenicrs587778868GRCh37Chr 13, 49037969: 49037969
16RB1NG_ 009009.1: g.1662319T> ASNVPathogenic
17RB1NM_ 000321.2(RB1): c.2227_ 2230dupTTGA (p.Lys745Aspfs)duplicationPathogenicrs587778836GRCh37Chr 13, 49039149: 49039152
18RB1NM_ 000321.2(RB1): c.2247T> A (p.Tyr749Ter)SNVPathogenicrs587778861GRCh37Chr 13, 49039169: 49039169
19RB1NG_ 009009.1: g.166501C> GSNVPathogenic
20RB1NM_ 000321.2(RB1): c.2453delG (p.Gly818Valfs)deletionPathogenicrs587778837GRCh37Chr 13, 49039468: 49039468
21RB1NM_ 000321.2(RB1): c.2490-1G> ASNVPathogenicrs587778838GRCh37Chr 13, 49047495: 49047495
22RB1NM_ 000321.2(RB1): c.2520+1G> ASNVPathogenicrs587778850GRCh37Chr 13, 49047527: 49047527
23RB1NM_ 000321.2(RB1): c.2525dupC (p.Glu843Terfs)duplicationPathogenicrs587778851GRCh37Chr 13, 49050841: 49050841
24RB1NM_ 000321.2(RB1): c.2663+2T> CSNVPathogenicrs587778839GRCh37Chr 13, 49050981: 49050981
25RB1NM_ 000321.2(RB1): c.305_ 306delGT (p.Cys102Tyrfs)deletionPathogenicrs587778825GRCh37Chr 13, 48916775: 48916776
26RB1NM_ 000321.2(RB1): c.409G> T (p.Glu137Ter)SNVPathogenic/ Likely pathogenicrs121913296GRCh37Chr 13, 48919244: 48919244
27RB1NM_ 000321.2(RB1): c.438_ 441delTGCT (p.Asn146Lysfs)deletionPathogenicrs587778841GRCh37Chr 13, 48919273: 48919276
28RB1NM_ 000321.2(RB1): c.446C> G (p.Ser149Ter)SNVPathogenicrs587778870GRCh37Chr 13, 48919281: 48919281
29RB1NM_ 000321.2(RB1): c.463dupT (p.Tyr155Leufs)duplicationPathogenicrs587778854GRCh37Chr 13, 48919298: 48919298
30RB1NM_ 000321.2(RB1): c.508G> T (p.Glu170Ter)SNVPathogenicrs587778826GRCh37Chr 13, 48921968: 48921968
31RB1NG_ 009009.1: g.5168-?_ 5303+?(2)undetermined variantPathogenic
32RB1NM_ 000321.2(RB1): c.72_ 74delGCC (p.Pro29del)deletionPathogenicrs587778823GRCh37Chr 13, 48878120: 48878122
33RB1NM_ 000321.2(RB1): c.103C> T (p.Gln35Ter)SNVPathogenicrs587778869GRCh37Chr 13, 48878151: 48878151
34RB1NM_ 000321.2(RB1): c.113_ 115delGCCinsCT (p.Gly38Alafs)indelPathogenicrs886037649GRCh38Chr 13, 48304025: 48304027
35RB1NM_ 000321.2(RB1): c.763C> T (p.Arg255Ter)SNVPathogenicrs587778842GRCh37Chr 13, 48936995: 48936995
36RB1NM_ 000321.2(RB1): c.795delA (p.Lys265Asnfs)deletionPathogenicrs587778827GRCh37Chr 13, 48937027: 48937027
37RB1NM_ 000321.2(RB1): c.884dupA (p.Asn295Lysfs)duplicationPathogenicrs587778828GRCh37Chr 13, 48939052: 48939052
38RB1NM_ 000321.2(RB1): c.937G> T (p.Glu313Ter)SNVPathogenicrs587778843GRCh37Chr 13, 48939105: 48939105
39RB1NM_ 000321.2(RB1): c.958C> T (p.Arg320Ter)SNVPathogenic/ Likely pathogenicrs121913300GRCh37Chr 13, 48941648: 48941648
40RB1NM_ 000321.2(RB1): c.1021A> T (p.Lys341Ter)SNVPathogenicrs587778855GRCh37Chr 13, 48941711: 48941711
41RB1NM_ 000321.2(RB1): c.1024delA (p.Thr342Leufs)deletionPathogenicrs587778844GRCh37Chr 13, 48941714: 48941714
42RB1NM_ 000321.2(RB1): c.1049+1G> ASNVPathogenicrs587776782GRCh37Chr 13, 48941740: 48941740
43RB1NM_ 000321.2(RB1): c.1060_ 1061delCA (p.Gln354Glufs)deletionPathogenicrs587778829GRCh37Chr 13, 48942673: 48942674
44RB1NM_ 000321.2(RB1): c.1147dupC (p.Gln383Profs)duplicationPathogenicrs587778830GRCh37Chr 13, 48947560: 48947560
45RB1NM_ 000321.2(RB1): c.1166T> A (p.Leu389Ter)SNVPathogenicrs587778845GRCh37Chr 13, 48947579: 48947579
46RB1NM_ 000321.2(RB1): c.1215+1G> ASNVPathogenicrs587776783GRCh37Chr 13, 48947629: 48947629
47RB1NM_ 000321.2(RB1): c.1216-1G> ASNVPathogenicrs587778831GRCh37Chr 13, 48951053: 48951053
48RB1NM_ 000321.2(RB1): c.1332+1G> ASNVPathogenicrs587778846GRCh37Chr 13, 48951171: 48951171
49RB1NM_ 000321.2(RB1): c.1332+1G> TSNVPathogenicrs587778846GRCh37Chr 13, 48951171: 48951171
50RB1NM_ 000321.2(RB1): c.1346G> T (p.Gly449Val)SNVPathogenicrs587778847GRCh37Chr 13, 48953743: 48953743
51RB1NM_ 000321.2(RB1): c.1363C> T (p.Arg455Ter)SNVPathogenic/ Likely pathogenicrs121913302GRCh37Chr 13, 48953760: 48953760
52RB1NM_ 000321.2(RB1): c.1456_ 1457delTT (p.Leu486Ilefs)deletionPathogenicrs587778832GRCh37Chr 13, 48954335: 48954336
53RB1NM_ 000321.2(RB1): c.1654C> T (p.Arg552Ter)SNVPathogenic/ Likely pathogenicrs121913303GRCh37Chr 13, 48955538: 48955538
54RB1NM_ 000321.2(RB1): c.1688G> A (p.Trp563Ter)SNVPathogenicrs587778863GRCh37Chr 13, 48955572: 48955572
55RB1NM_ 000321.2(RB1): c.1695+1G> ASNVPathogenicrs587778857GRCh37Chr 13, 48955580: 48955580
56RB1NM_ 000321.2(RB1): c.217delA (p.Arg73Glufs)deletionPathogenicrs587778840GRCh37Chr 13, 48881495: 48881495
57RB1NM_ 000321.2(RB1): c.219_ 220delAG (p.Arg73Serfs)deletionPathogenicrs587778862GRCh37Chr 13, 48881497: 48881498
58RB1NM_ 000321.2(RB1): c.227_ 228dupTA (p.Thr77Terfs)duplicationPathogenicrs587778824GRCh37Chr 13, 48881505: 48881506
59RB1NM_ 000321.2(RB1): c.2520+1delGdeletionPathogenicrs587776779GRCh37Chr 13, 49047527: 49047527
60RB1NM_ 000321.2(RB1): c.1960+2T> CSNVPathogenicrs587776780GRCh37Chr 13, 49030487: 49030487
61RB1NM_ 000321.2(RB1): c.1333C> T (p.Arg445Ter)SNVPathogenicrs3092891GRCh37Chr 13, 48953730: 48953730
62RB1NM_ 000321.2(RB1): c.1700C> T (p.Ser567Leu)SNVPathogenicrs137853292GRCh37Chr 13, 49027133: 49027133
63RB1NM_ 000321.2(RB1): c.2359C> T (p.Arg787Ter)SNVPathogenicrs137853293GRCh37Chr 13, 49039374: 49039374
64RB1NM_ 000321.2(RB1): c.2244delG (p.Glu748Aspfs)deletionPathogenicrs587776781GRCh37Chr 13, 49039166: 49039166
65RB1NM_ 000321.2(RB1): c.1049+1G> TSNVPathogenicrs587776782GRCh37Chr 13, 48941740: 48941740
66RB1NM_ 000321.2(RB1): c.1072C> T (p.Arg358Ter)SNVPathogenic/ Likely pathogenicrs121913301GRCh37Chr 13, 48942685: 48942685
67RB1RB1, 5-BP DEL, EX8deletionPathogenic
68RB1NM_ 000321.2(RB1): c.979_ 1033dup55 (p.Thr345Lysfs)duplicationPathogenicGRCh37Chr 13, 48941669: 48941723
69RB1NM_ 000321.2(RB1): c.1760_ 1769delAATCTGCTTG (p.Glu587Valfs)deletionPathogenicrs587776784GRCh37Chr 13, 49027193: 49027202
70RB1NM_ 000321.2(RB1): c.1949_ 1957delTTTATAAAA (p.Phe650_ Lys928del)deletionPathogenicrs587776785GRCh37Chr 13, 49030474: 49030482
71RB1NM_ 000321.2(RB1): c.2212-1G> ASNVPathogenicrs587776786GRCh37Chr 13, 49039133: 49039133
72RB1NM_ 000321.2(RB1): c.-189G> TSNVPathogenicrs387906520GRCh37Chr 13, 48877860: 48877860
73RB1NM_ 000321.2(RB1): c.-198G> ASNVPathogenicrs387906521GRCh37Chr 13, 48877851: 48877851
74RB1NM_ 000321.2(RB1): c.1981C> T (p.Arg661Trp)SNVPathogenicrs137853294GRCh37Chr 13, 49033844: 49033844
75RB1RB1, GLN675TERSNVPathogenic
76RB1NM_ 000321.2(RB1): c.2211G> A (p.Glu737=)SNVPathogenicrs587776787GRCh37Chr 13, 49037971: 49037971
77RB1NM_ 000321.2(RB1): c.1666C> T (p.Arg556Ter)SNVPathogenic/ Likely pathogenicrs121913304GRCh37Chr 13, 48955550: 48955550
78RB1NM_ 000321.2(RB1): c.1439_ 1441delACA (p.Asn480del)deletionPathogenicrs587776788GRCh37Chr 13, 48954318: 48954320
79RB1NM_ 000321.2(RB1): c.2134T> C (p.Cys712Arg)SNVPathogenicrs137853296GRCh37Chr 13, 49037894: 49037894
80RB1NM_ 000321.2(RB1): c.607+1G> TSNVPathogenicrs587776789GRCh37Chr 13, 48923160: 48923160
81RB1NM_ 000321.2(RB1): c.1818T> A (p.Tyr606Ter)SNVPathogenicrs137853297GRCh37Chr 13, 49030343: 49030343
82RB1NM_ 000321.2(RB1): c.43_ 65dup23 (p.Pro23Leufs)duplicationPathogenicrs587776790GRCh37Chr 13, 48878091: 48878113
83RB1NM_ 000321.2(RB1): c.2490-1398A> GSNVPathogenicrs587776791GRCh37Chr 13, 49046098: 49046098
84RB1NM_ 000321.2(RB1): c.1421+12_ 1421+32deldeletionPathogenicrs587781256GRCh37Chr 13, 48954232: 48954252
85RB1NM_ 000321.2(RB1): c.1907delT (p.Phe636Serfs)deletionPathogenicrs587781257GRCh37Chr 13, 49030432: 49030432
86RB1NM_ 000321.2(RB1): c.54_ 79del26 (p.Glu19Profs)deletionPathogenicrs727504120GRCh37Chr 13, 48878102: 48878127
87RB1NM_ 000321.2(RB1): c.1191delA (p.Glu398Lysfs)deletionPathogenicrs727504121GRCh37Chr 13, 48947604: 48947604
88RB1NM_ 000321.2(RB1): c.1401_ 1411dupATTATCCATTC (p.Gln471Hisfs)duplicationPathogenicrs797044649GRCh37Chr 13, 48954200: 48954210
89RB1NM_ 000321.2(RB1): c.1696-1G> ASNVPathogenicrs794727199GRCh37Chr 13, 49027128: 49027128
90RB1NM_ 000321.2(RB1): c.2370C> A (p.Tyr790Ter)SNVPathogenicrs794727372GRCh37Chr 13, 49039385: 49039385
91RB1NM_ 000321.2(RB1): c.297G> A (p.Trp99Ter)SNVPathogenicrs794727481GRCh37Chr 13, 48916767: 48916767
92RB1NM_ 000321.2(RB1): c.1154T> G (p.Leu385Ter)SNVPathogenicrs878853947GRCh38Chr 13, 48373431: 48373431
93RB1NM_ 000321.2(RB1): c.1814+3A> CSNVLikely pathogenicrs376886420GRCh37Chr 13, 49027250: 49027250
94RB1NM_ 000321.2(RB1): c.2053C> T (p.Gln685Ter)SNVPathogenicrs878853949GRCh37Chr 13, 49033916: 49033916
95RB1NM_ 000321.2(RB1): c.376delA (p.Ile126Serfs)deletionPathogenicrs886042357GRCh37Chr 13, 48916846: 48916846
96RB1NM_ 000321.2(RB1): c.2548C> T (p.Gln850Ter)SNVPathogenicrs886042935GRCh37Chr 13, 49050864: 49050864
97RB1NM_ 000321.2(RB1): c.1510C> T (p.Gln504Ter)SNVPathogenicrs886043247GRCh37Chr 13, 48955394: 48955394
98RB1NM_ 000321.2(RB1): c.396delT (p.Phe132Leufs)deletionPathogenicrs886043313GRCh37Chr 13, 48919231: 48919231
99RB1NM_ 000321.2(RB1): c.2489+1G> CSNVPathogenicrs764754259GRCh37Chr 13, 49039505: 49039505
100RB1NM_ 000321.2(RB1): c.596T> A (p.Leu199Ter)SNVLikely pathogenicrs121913298GRCh37Chr 13, 48923148: 48923148
101RB1NM_ 000321.2(RB1): c.2029G> T (p.Glu677Ter)SNVPathogenicrs1060503067GRCh38Chr 13, 48459756: 48459756
102RB1NM_ 000321.2(RB1): c.1215+2T> GSNVLikely pathogenicrs1060503074GRCh38Chr 13, 48373494: 48373494
103RB1NM_ 000321.2(RB1): c.2194_ 2197delCCTC (p.Pro732Metfs)deletionPathogenicrs1060503075GRCh37Chr 13, 49037954: 49037957
104RB1NM_ 000321.2(RB1): c.967G> T (p.Glu323Ter)SNVPathogenicrs1060503077GRCh38Chr 13, 48367521: 48367521
105RB1NM_ 000321.2(RB1): c.1328C> A (p.Ser443Ter)SNVPathogenicrs1060503079GRCh38Chr 13, 48377030: 48377030
106RB1NM_ 000321.2(RB1): c.1673_ 1674dupTG (p.Glu559Trpfs)duplicationPathogenicGRCh38Chr 13, 48381421: 48381422
107RB1NM_ 000321.2(RB1): c.1960G> C (p.Val654Leu)SNVPathogenicrs483352690GRCh38Chr 13, 48456349: 48456349
108RB1NM_ 000321.2(RB1): c.1390-14A> GSNVLikely pathogenicrs9535023GRCh38Chr 13, 48380039: 48380039
109RB1NM_ 000321.2(RB1): c.1389+1G> TSNVLikely pathogenicrs1060503087GRCh38Chr 13, 48379651: 48379651
110RB1NM_ 000321.2(RB1): c.1696-12T> GSNVPathogenicrs1060503088GRCh38Chr 13, 48452981: 48452981
111RB1NM_ 000321.2(RB1): c.37_ 65del29 (p.Ala13Thrfs)deletionPathogenicGRCh38Chr 13, 48303949: 48303977
112RB1NC_ 000013.11: g.(?_ 48342599)_ (48345199_ ?)deldeletionPathogenicGRCh38Chr 13, 48342599: 48345199
113RB1NC_ 000013.11: g.(?_ 48379594)_ (48381443_ ?)deldeletionLikely pathogenicGRCh38Chr 13, 48379594: 48381443
114RB1NM_ 000321.2(RB1): c.1399C> T (p.Arg467Ter)SNVPathogenicrs398123331GRCh37Chr 13, 48954198: 48954198
115RB1NM_ 000321.2(RB1): c.1585dupT (p.Tyr529Leufs)duplicationPathogenicrs398123332GRCh37Chr 13, 48955469: 48955469
116RB1NM_ 000321.2(RB1): c.2067_ 2079delGAATGAGTATGAAinsCAC (p.Gln689Hisfs)indelPathogenicrs398123333GRCh37Chr 13, 49033930: 49033942

Cosmic variations for Retinoblastoma:

8 (show all 38)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM889RB1eye,retina,retinoblastoma,NSc.2158A>Tp.K720*29
2COSM890RB1eye,retina,retinoblastoma,NSc.409G>Tp.E137*29
3COSM3724517RB1eye,retina,retinoblastoma,NSc.862-5T>Gp.?29
4COSM895RB1eye,retina,retinoblastoma,NSc.1363C>Tp.R455*29
5COSM1030RB1eye,retina,retinoblastoma,NSc.1961-1G>Ap.?29
6COSM521KRASeye,retina,retinoblastoma,NSc.35G>Ap.G12D29
7COSM878RB1eye,retina,retinoblastoma,NSc.751C>Tp.R251*29
8COSM891RB1eye,retina,retinoblastoma,NSc.958C>Tp.R320*29
9COSM1636648RB1eye,retina,retinoblastoma,NSc.2106+2T>Gp.?29
10COSM936RB1eye,retina,retinoblastoma,NSc.1183C>Tp.Q395*29
11COSM888RB1eye,retina,retinoblastoma,NSc.1666C>Tp.R556*29
12COSM882RB1eye,retina,retinoblastoma,NSc.2152G>Ap.D718N29
13COSM876RB1eye,retina,retinoblastoma,NSc.160G>Tp.E54*29
14COSM887RB1eye,retina,retinoblastoma,NSc.1654C>Tp.R552*29
15COSM764PIK3CAeye,retina,retinoblastoma,NSc.1634A>Gp.E545G29
16COSM13117RB1eye,retina,retinoblastoma,NSc.2053C>Tp.Q685*29
17COSM877RB1eye,retina,retinoblastoma,NSc.341C>Ap.S114*29
18COSM1041RB1eye,retina,retinoblastoma,NSc.1049+1G>Tp.?29
19COSM943RB1eye,retina,retinoblastoma,NSc.763C>Tp.R255*29
20COSM1050RB1eye,retina,retinoblastoma,NSc.1421G>Ap.S474N29
21COSM880RB1eye,retina,retinoblastoma,NSc.1333C>Tp.R445*29
22COSM910RB1eye,retina,retinoblastoma,NSc.1467C>Ap.C489*29
23COSM144722RB1eye,retina,retinoblastoma,NSc.265-2A>Cp.?29
24COSM1026RB1eye,retina,retinoblastoma,NSc.2326-2A>Cp.?29
25COSM1016RB1eye,retina,retinoblastoma,NSc.1960+1G>Ap.?29
26COSM3724518RB1eye,retina,retinoblastoma,NSc.2520+4A>Gp.?29
27COSM1015RB1eye,retina,retinoblastoma,NSc.1215+1G>Ap.?29
28COSM1014RB1eye,retina,retinoblastoma,NSc.1216-2A>Gp.?29
29COSM1040RB1eye,retina,retinoblastoma,NSc.1960+2T>Cp.?29
30COSM938RB1eye,retina,retinoblastoma,NSc.967G>Tp.E323*29
31COSM3724510RB1eye,retina,retinoblastoma,NSc.2527G>Tp.E843*29
32COSM942RB1eye,retina,retinoblastoma,NSc.2063T>Cp.L688P29
33COSM1013RB1eye,retina,retinoblastoma,NSc.1389+1G>Cp.?29
34COSM903RB1eye,retina,retinoblastoma,NSc.1494T>Ap.Y498*29
35COSM911RB1eye,retina,retinoblastoma,NSc.1166T>Ap.L389*29
36COSM1047RB1eye,retina,retinoblastoma,NSc.982A>Cp.N328H29
37COSM520KRASeye,retina,retinoblastoma,NSc.35G>Tp.G12V29
38COSM1017RB1eye,retina,retinoblastoma,NSc.380+1G>Tp.?29

Copy number variations for Retinoblastoma from CNVD:

6 (show top 50)    (show all 60)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137531127800000LossTP73Retinoblastoma
2171871141465960179620513GainMCL1Retinoblastoma
3171881141465960179620513GainMUC1Retinoblastoma
4171891141465960179620513GainSHC1Retinoblastoma
53590316870000069500000Copy numberRetinoblastoma
63976110119100000135374737Copy numberMGMTRetinoblastoma
74968611110000000120700000LossIGSF4Retinoblastoma
85153411127676090128202918LosseETS1Retinoblastoma
953561113100000036400000Copy numberCD44Retinoblastoma
1053578113100000036400000GainPAX6Retinoblastoma
1153580113100000036400000GainWT1Retinoblastoma
1257117116310000076700000Copy numberGSTP1Retinoblastoma
136448212128700000132349534LossCHFRRetinoblastoma
1475253131840000022200000Copy numberRetinoblastoma
1576125132780000031100000LossBRCA2Retinoblastoma
1676619133362325978516556LosseARLTS1Retinoblastoma
1776620133362325978516556LosseRB1Retinoblastoma
1877033133950000052200000Copy numberRetinoblastoma
1977039133950000052200000DeletionHTR2ARetinoblastoma
2077041133950000052200000DeletionNUFIP1Retinoblastoma
2177043133950000052200000DeletionPCDH17Retinoblastoma
2277045133950000052200000DeletionPCDH8Retinoblastoma
2377635134620000048900000Copy numberRetinoblastoma
2477647134620000048900000LossRB1Retinoblastoma
2577992134887788349056026MutationRB1Retinoblastoma
2680983141106368585Copy numberRetinoblastoma
2787295147290000078400000GainMLH3Retinoblastoma
2889229151410000018400000Copy numberRetinoblastoma
2994758157040000073100000Copy numberRetinoblastoma
3098276161670000027600000GainPYCARDRetinoblastoma
31102221165067462557636204LosseCYLDRetinoblastoma
32102222165067462557636204LosseRBL2Retinoblastoma
33106052168560000087200000LossCDH13Retinoblastoma
3411654517680000011200000LossTP53Retinoblastoma
35119289181090000015400000Copy numberRetinoblastoma
361206301829000007200000Copy numberRetinoblastoma
3712414819163811651Copy numberRetinoblastoma
3813775321512036017242742GainDDX1Retinoblastoma
3913775421512036017242742GainMYCNRetinoblastoma
4014628124760000061100000Copy numberMSH6Retinoblastoma
41155742205790000062435964LossGATA5Retinoblastoma
4216607131199501827Copy numberRetinoblastoma
431791783870000011500000GainVHLRetinoblastoma
44200479555800000115200000GainAPCRetinoblastoma
45204222610808358827841GainCCND3Retinoblastoma
46204223610808358827841GainDEKRetinoblastoma
47204224610808358827841GainE2F3Retinoblastoma
48204225610808358827841GainIRF4Retinoblastoma
49204226610808358827841GainPIM1Retinoblastoma
502068736149100000152600000GainESRRetinoblastoma

Expression for genes affiliated with Retinoblastoma

About this section
Search GEO for disease gene expression data for Retinoblastoma.

Pathways for genes affiliated with Retinoblastoma

About this section

Pathways related to Retinoblastoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 63)
idSuper pathwaysScoreTop Affiliating Genes
110.2RBBP4, RBBP7
210.1RB1, RBL1, RBL2
310.1E2F1, RB1, RBBP8
410.1CCND1, CDK4, RB1
510.0E2F1, MDM2, RB1
610.0E2F1, MDM2, RB1
710.0CCND1, MDM2, RB1
810.0CCND1, CCND3, E2F1
910.0CCND1, CCND3, CDK4
10
Show member pathways
10.0E2F4, RBL1, TFDP1
119.9CCND1, CDK4, E2F1, RB1
12
Show member pathways
9.9PRDM2, RBBP4, RBBP5, RBBP7
139.9CCND1, E2F1, RBBP4, RBBP7
149.9CDK4, E2F1, MDM2, RB1
15
Show member pathways
9.9CCND1, CCND3, CDK4, RB1
169.8E2F1, E2F4, RB1, RBL1, RBL2
179.8CCND1, CCND3, MDM2, RBL2
18
Show member pathways
9.8CCND1, E2F1, E2F3, TFDP1
19
Show member pathways
9.8CCND1, CCND3, CDK4, MDM2
209.8CCND1, CCND3, CDK4, MDM2
219.8E2F1, MDM2, RB1, RBBP4, RBBP7
229.8CCND3, CDK4, E2F1, RB1, RBL2
239.7CCND1, CDK4, E2F1, MDM2, RB1
249.7CDK4, RBBP4, RBBP7, RBL1, TFDP1
25
Show member pathways
9.7E2F1, E2F4, RBL1, RBL2, TFDP1
26
Show member pathways
9.7E2F1, E2F2, E2F3, E2F4, RB1
27
Show member pathways
9.7CCND1, E2F4, RBL1, RBL2, TFDP1
28
Show member pathways
9.7E2F4, RB1, RBBP4, RBBP7, RBL1, RBL2
299.7CCND1, CCND3, CDK4, MDM2, RBL2
309.6E2F4, MDM2, RB1, RBBP4, TFDP1
319.6CCND1, E2F1, E2F2, E2F3, MDM2
329.6CCND1, CDK4, E2F1, E2F2, E2F3, RB1
33
Show member pathways
9.6CCND1, CDK4, E2F1, E2F2, E2F3, RB1
34
Show member pathways
9.5CCND1, CCND3, CDK4, E2F1, MDM2, RB1
35
Show member pathways
9.5E2F1, E2F2, E2F3, E2F4, RB1, RBBP8
36
Show member pathways
9.5ARID4A, CCND1, CDK4, RBBP4, RBBP5, RBBP7
379.4CDK4, E2F1, E2F2, E2F3, MDM2, TFDP1
389.4CCND1, CCND3, CDK4, MDM2, RB1, RBL1
39
Show member pathways
9.4CCND1, CDK4, E2F1, E2F2, E2F3, MDM2
409.4CCND1, CDK4, E2F1, E2F2, E2F3, MDM2
41
Show member pathways
9.4CCND1, CDK4, E2F1, E2F2, E2F3, MDM2
42
Show member pathways
9.4CCND1, CDK4, E2F1, E2F2, E2F3, MDM2
439.4CCND1, CCND3, CDK4, E2F1, E2F2, E2F3
449.3CCND1, E2F1, E2F2, E2F3, E2F4, RB1
459.3CCND1, CCND3, CDK4, E2F1, MDM2, RB1
46
Show member pathways
9.2CCND1, CCND3, CDK4, E2F1, E2F4, RB1
479.2CCND1, CDK4, E2F1, E2F2, E2F3, E2F4
48
Show member pathways
9.2CCND1, CDK4, E2F1, E2F2, E2F3, E2F4
49
Show member pathways
9.2CCND1, CCND3, CDK4, E2F1, E2F2, E2F4
50
Show member pathways
9.1E2F1, E2F4, MDM2, RBBP4, RBBP7, RBBP8

GO Terms for genes affiliated with Retinoblastoma

About this section

Cellular components related to Retinoblastoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ESC/E(Z) complexGO:003509811.0RBBP4, RBBP7
2Rb-E2F complexGO:003518910.8E2F1, RB1
3NuRD complexGO:001658110.8RBBP4, RBBP7
4cyclin-dependent protein kinase holoenzyme complexGO:000030710.8CCND1, CCND3, CDK4
5transcriptional repressor complexGO:00170539.9ARID4A, CCND1, RBBP8
6transcription factor complexGO:00056679.5CDK4, E2F1, E2F2, E2F3, E2F4, RB1
7nucleoplasmGO:00056548.1ARID4A, CCND1, CCND3, CDK4, DDX1, E2F1
8nucleusGO:00056347.8ARID4A, CCND1, CCND3, CDK4, DDX1, E2F1

Biological processes related to Retinoblastoma according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1cellular response to xenobiotic stimulusGO:007146611.0E2F1, RB1
2negative regulation of transcription involved in G1/S transition of mitotic cell cycleGO:007193011.0E2F1, RB1
3cell cycle checkpointGO:000007511.0RB1, RBBP8
4regulation of G1/S transition of mitotic cell cycleGO:200004511.0CCND1, E2F1
5lens fiber cell apoptotic processGO:199008611.0E2F1, E2F2
6anoikisGO:004327611.0E2F1, TFDP1
7regulation of insulin receptor signaling pathwayGO:004662610.9CCND3, CDK4
8regulation of lipid kinase activityGO:004355010.9RB1, RBL1, RBL2
9response to iron ionGO:001003910.9CCND1, MDM2
10response to magnesium ionGO:003202610.9CCND1, MDM2
11negative regulation of cell cycle arrestGO:007115710.8CCND1, CDK4, MDM2
12positive regulation of cell cycleGO:004578710.8CCND1, CDK4, MDM2
13histone deacetylationGO:001657510.8ARID4A, RBBP4, RBBP7
14negative regulation of fat cell proliferationGO:007034510.8E2F1, E2F3, TFDP1
15negative regulation of gene expressionGO:001062910.7MDM2, RB1, RBL1, RBL2
16response to steroid hormoneGO:004854510.7CCND1, MDM2, RBBP7
17G1/S transition of mitotic cell cycleGO:000008210.7CCND1, CDK4, RB1, RBBP8
18regulation of signal transduction by p53 class mediatorGO:190179610.7MDM2, RBBP4, RBBP7, RBBP8
19regulation of transcription involved in G1/S transition of mitotic cell cycleGO:000008310.6E2F1, E2F4, RB1, TFDP1
20regulation of cell proliferationGO:004212710.5CCND3, CDK4, E2F4, RBBP9
21cell divisionGO:005130110.5CCND1, CCND3, CDK4, RB1, RBBP8
22covalent chromatin modificationGO:001656910.5RB1, RBBP4, RBBP5, RBBP7, RBL1, RBL2
23negative regulation of transcription, DNA-templatedGO:004589210.5ARID4A, E2F1, MDM2, RB1, RBBP7
24DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.4E2F1, E2F4, MDM2, RBL2, TFDP1
25regulation of transcription from RNA polymerase II promoterGO:000635710.3ARID4A, RB1, RBBP8, RBL1, RBL2, TFDP1
26positive regulation of transcription from RNA polymerase II promoterGO:004594410.2ARID4A, E2F1, E2F4, PRDM2, RB1, RBL1
27negative regulation of transcription from RNA polymerase II promoterGO:000012210.1CCND1, CCND3, E2F1, MDM2, RB1, RBBP7
28regulation of cell cycleGO:00517269.9CCND1, CCND3, CDK4, E2F1, E2F2, RB1
29cell cycleGO:00070499.2CCND1, CCND3, CDK4, E2F1, E2F2, E2F3
30regulation of transcription, DNA-templatedGO:00063558.9ARID4A, CCND1, DDX1, E2F1, E2F2, E2F3
31transcription, DNA-templatedGO:00063518.1ARID4A, CCND1, DDX1, E2F1, E2F2, E2F3

Molecular functions related to Retinoblastoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase regulator activityGO:001653811.0CCND1, CDK4
2promoter-specific chromatin bindingGO:199084110.9E2F4, RBL1, RBL2
3cyclin-dependent protein serine/threonine kinase activityGO:000469310.8CCND1, CCND3, CDK4
4histone deacetylase activityGO:000440710.8ARID4A, RBBP4, RBBP7
5core promoter bindingGO:000104710.7E2F1, E2F2, E2F3, RB1
6protein dimerization activityGO:004698310.5E2F1, E2F2, E2F3, E2F4
7transcription factor activity, sequence-specific DNA bindingGO:00037009.7ARID4A, E2F1, E2F2, E2F3, E2F4, PRDM2
8DNA bindingGO:00036779.5ARID4A, DDX1, E2F1, E2F2, E2F3, E2F4
9transcription factor bindingGO:00081349.4CCND1, E2F1, E2F2, E2F4, RB1, RBL1
10protein bindingGO:00055158.3CCND1, CCND3, CDK4, DDX1, E2F1, E2F2

Sources for Retinoblastoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet